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Abstract
IMPORTANCE—The risk of cardiovascular disease (CVD) after infection is poorly understood.
OBJECTIVE—To determine whether hospitalization for pneumonia is associated with an 
increased short-term and long-term risk of CVD.
DESIGN, SETTINGS, AND PARTICIPANTS—We examined 2 community-based cohorts: the 
Cardiovascular Health Study (CHS, n = 5888; enrollment age, ≥65 years; enrollment period, 
1989–1994) and the Atherosclerosis Risk in Communities study (ARIC, n = 15 792; enrollment 
age, 45-64 years; enrollment period, 1987–1989). Participants were followed up through 
December 31, 2010. We matched each participant hospitalized with pneumonia to 2 controls. 
Pneumonia cases and controls were followed for occurrence of CVD over 10 years after matching. 
We estimated hazard ratios (HRs) for CVD at different time intervals, adjusting for demographics, 
CVD risk factors, subclinical CVD, comorbidities, and functional status.
EXPOSURES—Hospitalization for pneumonia.
MAIN OUTCOMES AND MEASURES—Incident CVD (myocardial infarction, stroke, and 
fatal coronary heart disease).
RESULTS—Of 591 pneumonia cases in CHS, 206 had CVD events over 10 years after 
pneumonia hospitalization. Compared with controls, CVD risk among pneumonia cases was 
highest during the first year after hospitalization and remained significantly higher than among 
controls through 10 years. In ARIC, of 680 pneumonia cases, 112 had CVD events over 10 years 
after hospitalization. After the second year, CVD risk among pneumonia cases was not 
significantly higher than among controls.
Pneumonia
Cases Controls HR (95% CI)
CHS
No. of participants 591 1182
CVD events
 0-30 d 54 6 4.07 (2.86-5.27)
 31-90 d 11 9 2.94 (2.18-3.70)
 91 d-1 y 22 55 2.10 (1.59-2.60)
 9-10 y 4 12 1.86 (1.18-2.55)
ARIC
No. of participants 680 1360
CVD events
 0-30 d 4 3 2.38 (1.12-3.63)
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 31-90 d 4 0 2.40 (1.23-3.47)
 91 d-1 y 11 8 2.19 (1.20-3.19)
 1-2 y 8 7 1.88 (1.10-2.66)
CONCLUSIONS AND RELEVANCE—Hospitalization for pneumonia was associated with 
increased short-term and long-term risk of CVD, suggesting that pneumonia may be a risk factor 
for CVD.
Cardiovascular disease (CVD) is the principal cause of morbidity and mortality worldwide.1 
In the United States, there are about 725 000 new cases of myocardial infarction and 795 
000 new cases of stroke,2 and 264 000 people die due to these conditions each year.1 
Therefore, characterizing the risk factors for CVD is important to design optimal preventive 
strategies.
Infections can induce demand ischemia, endothelial dysfunction, procoagulant changes in 
blood, and inflammatory changes in atherosclerotic plaques.3,4 Alone or in combination, 
these effects can increase the short-term risk of cardiovascular events.3,4 However, because 
heightened systemic inflammatory and procoagulant activity can persist long after infections 
resolve,5,6 the effect of infections on CVD risk could also extend for several months or 
years.
Several clinical studies have documented a 2-fold to 8-fold increase in the risk of CVD 
within the first 30 days after respiratory infections.3 A few studies also examined the 
association between infection and subsequent long-term risk of CVD and their results have 
been conflicting.7-10 Characterizing the short-term and long-term risk of CVD after infection 
is important because it could suggest that infection is a risk factor for CVD and explain why 
patients with infections have increased short-term and long-term morbidity and 
mortality.11,12
In this study, we analyzed data from participants enrolled in 2 community-based, 
observational, multicenter cohorts to determine the risk of CVD. We determined whether the 
risk of CVD varies over a 10-year period after pneumonia and whether the association 
persists after adjusting for traditional and novel cardiovascular risk factors. We chose 
pneumonia because respiratory tract infections have been consistently associated with 
increased risk of CVD,3,7 pneumonia is a well-characterized infectious syndrome that 
affects 1.2% of the population in the northern hemisphere each year,13 and it is the most 
common medical diagnosis responsible for hospitalizations in the United States.14
Methods
Study Design
We conducted a matched-cohort study nested within 2 population-based, multicenter, 
observational cohorts that were followed up for over 21 years: the Cardiovascular Health 
Study (CHS, n = 5888) cohort and the Atherosclerosis Risk in Communities (ARIC, n = 15 
792) cohort. The institutional review boards at each CHS and ARIC study site approved the 
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studies. All participants gave informed consent. We identified pneumonia hospitalizations 
within the first 15 years. Within each cohort, we used incidence density sampling to match 
participants hospitalized with pneumonia to 2 controls. We examined risk of CVD at various 
time intervals in the first 10 years after pneumonia occurred. We did not combine the 
cohorts due to differences in baseline clinical characteristics and risk of CVD among CHS 
and ARIC participants.15,16 We first examined CHS and then replicated our analyses in 
ARIC.
Participants and Data Collection
The CHS and ARIC studies recruited noninstitutionalized community-dwelling adults 
between 1987 and 1989 (ARIC) and between 1989 and 1994 (CHS).15,16 At enrollment, 
participants were 65 years or older in CHS and aged 45 to 64 years in ARIC.15,16 Details of 
eligibility criteria and study procedures in each cohort have been described elsewhere 
(eMethods 1 in the Supplement).15,16 We chose these cohorts because they were designed to 
understand the incidence, risk factors, and progression of CVD15,16; their methodology for 
the ascertainment of cardiovascular events was rigorous, comparable, and validated17-20; 
and the age range of their participants would maximize the generalizability of our results.
In both cohorts, baseline evaluation included standardized physical examination, diagnostic 
testing, laboratory evaluation, and questionnaires on health status, medical history, and 
lifestyle habits to determine cardiovascular risk factors. Thereafter, regular study visits and 
telephone follow ups were conducted to update cardiovascular risk factors.15,16 Participants 
were followed up through December 31, 2010.
A combination of annual study visits, telephone follow ups, review of Medicare Provider 
Utilization files (CHS only), local hospitalization records, death certificates from state vital 
statistics offices, and local newspaper obituaries were used for identification of new 
cardiovascular events, hospital admissions, and mortality.15,16
Adjudication of Pneumonia Hospitalizations
Hospital discharge abstracts were obtained for all hospitalizations. We used previously 
validated International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) codes 480 through 487 in the first 5 discharge diagnoses fields to identify 
pneumonia hospitalizations.21,22 We reviewed the medical charts of 158 pneumonia 
admissions identified by this approach in CHS. Clinical diagnoses of pneumonia were 
present in 89% of cases and in 88% of cases for radiographic diagnoses.23 We identified 
severe pneumonia (pneumonia with organ dysfunction) using previously validated ICD-9-
CM codes for severe sepsis.24
Cardiovascular Disease
Our primary outcome was incident (new-onset) CVD, including myocardial infarction, 
stroke, and fatal coronary heart disease. All CVD events were centrally adjudicated using 
standardized clinical, laboratory, and radiological criteria as previously described (eTable 1 
in the Supplement).15-18
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Selection of the Analysis Cohorts
We excluded participants who had CVD at study entry, developed CVD before pneumonia 
occurred, or had missing information on CVD. Among the remaining eligible participants, 
we built nested cohorts of patients with and without pneumonia within CHS and ARIC using 
the “incidence density sampling without replacement of controls” approach because it 
produces unbiased estimates.25 Briefly, we identified participants who were hospitalized 
with pneumonia in each cohort and determined the time (in days) from their enrollment to 
first hospitalization with pneumonia (ie, time to pneumonia). We then matched each 
participant with pneumonia by age (±5 years) to 2 controls randomly selected from 
participants who were alive and actively followed in the study at least for the same period 
(time to pneumonia) but did not have pneumonia or CVD during that time. Once chosen, the 
participants could not be sampled again. Participants initially selected as a control could be 
hospitalized with pneumonia at a later time.
Covariates
Depending on availability in each study, covariates (eTable 2 in the Supplement) included 
demographics (age, sex, and race), cardiovascular risk factors (hypertension; diabetes 
mellitus; total, high-density lipoprotein, and low-density lipoprotein cholesterol; smoking 
[history of smoking and pack-years smoked]; alcohol abuse;26 atrial fibrillation; body mass 
index [BMI, calculated as weight in kilograms divided by height in meters squared]; chronic 
kidney disease; and serum levels of C-reactive protein);27,28 subclinical CVD (presence of 
subclinical disease based on measurements in various vascular beds in CHS and in 
individual measures of vascular disease in ARIC);29 lung function (percentage of the 
predicted forced expiratory volume in the first second of expiration [FEV1]); measures of 
functional status (trajectories of activities of daily living [ADL] and independent activities 
of daily living [IADL] over time);30 and cognition (trajectories of modified mini-mental 
status examination scores over time) (eMethods 2 in the Supplement).30 In CHS, covariates 
were longitudinally updated for the first 10 years of the study. We used the most recent 
value or trajectories of longitudinal data before participant’s inclusion in the nested analysis 
cohort. In ARIC, only baseline values were included. We considered, but did not include, 
statin usage before pneumonia hospitalization because its prevalence at baseline was very 
low and similar (2.3% in CHS) in participants with and without pneumonia and it remained 
similar between the 2 groups over the first 10 years. Less than 5% of data for each covariate 
was missing.
Statistical Analyses
We compared distributions of categorical and continuous variables using χ2 tests, 2-sample t 
tests, or Wilcoxon 2-sample tests, as appropriate.
To examine the association between pneumonia and subsequent risk of CVD in the nested 
analysis cohorts, we used the Gray piecewise constant time-varying coefficients model31 to 
estimate the hazard ratios (HRs) and their 95% CIs at prespecified postpneumonia intervals 
(0-30 days, 31-90 days, 91 days-1 year, and then yearly up to year 10) based on prior 
studies.7,8,32 We chose the Gray model for 2 reasons. First, the Gray model does not assume 
time-invariant effects of the exposure (as opposed to traditional models such as Cox 
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proportional hazards model).31 This is important because the association between 
pneumonia and CVD varies over time.7,8,32 Second, the Gray model accounts for 
differences in exposure time. This is important because participants with pneumonia had 
shorter survival times compared with controls within each time interval. Participants were 
censored at the time of their first CVD event, death, or loss to follow up. Using the Gray 
model, we conducted unadjusted and adjusted analyses adjusting for the covariates 
described above. The HRs for the covariates did not vary over time after pneumonia and 
thus a single HR was estimated for each covariate. We show the risk of CVD for common 
traditional risk factors, including hypertension, smoking, and diabetes.
We also constructed failure plots using the Gray model. We computed these curves using the 
covariates described above. For each covariate, we computed the 25th, 50th, and 75th 
percentiles and then used these values to obtain the corresponding curves from the Gray 
model for participants with and without pneumonia.
We conducted stratified analysis to assess whether the association between pneumonia and 
CVD was observed for severe and nonsevere pneumonia cases. In addition, we conducted 3 
sensitivity analyses. First, we explored whether the association between pneumonia and 
CVD in our primary analysis was specific to this infection or whether it was also present 
with other acute illnesses that lead to hospitalization. We therefore repeated our primary 
analysis but matched each participant hospitalized with pneumonia to a participant 
hospitalized for other reasons (excluding hospitalizations for CVD and infections). Second, 
we restricted our analysis to include only pneumonia cases that had pneumonia recorded in 
the primary (first) discharge diagnosis field of their hospitalization along with their 
corresponding controls. This stringent definition reduces the sensitivity of capturing 
hospitalizations with pneumonia but maximizes the probability that pneumonia was the 
primary reason for these admissions.22 Third, we repeated our primary analysis excluding 
hospitalizations in which both heart failure and pneumonia were recorded. We excluded 
these cases because these individuals could have had undiagnosed CVD (which may 
manifest as heart failure), or these hospitalizations may have been solely due to heart failure 
rather than pneumonia (as it is often difficult to clinically distinguish between them).
The cumulative risk of CVD and mortality was calculated for both cohorts using all 
participants hospitalized with pneumonia. We used a complete case approach (ie, 
observations of participants with missing data were omitted) to estimate the number of cases 
and controls that were at risk and that developed CVD at each time interval as well as the 
corresponding HRs for CVD between the 2 groups. All tests were 2-sided and a P value of 
less than .05 was considered statistically significant. All statistical analyses were performed 
using SAS (SAS Institute), version 9.2, and R statistical software, version 2.1.
Results
Cardiovascular Health Study
There were 4265 eligible participants. After matching, the analysis cohort nested within 
CHS consisted of 1773 (591 pneumonia cases and 1182 controls) participants (Figure 1A). 
Of note, 54 controls (4.5%) developed pneumonia after they were identified as a control 
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using incidence density sampling; however, they were still considered controls in all 
analyses. The average age of patients with pneumonia was 73 years, they had a high burden 
of cardiovascular risk factors, and most were functional (92% had either 1 or no ADL 
impairments) and had normal or near-normal cognition (93% had an average modified mini-
mental status examination score of 75) before pneumonia occurred (Table and eTable 3 in 
the Supplement). Of the 591 pneumonia cases, 211 cases (35.7%) had severe pneumonia. 
Mortality was high following pneumonia hospitalization. The cumulative mortality in 
pneumonia cases at 30 days after pneumonia was 111 deaths (18.8%); at 90 days, 146 deaths 
(24.7%); at 1 year, 212 deaths (35.9%); at 5 years, 348 deaths (58.9%); and at 10 years, 419 
deaths (70.9%). Among controls, the corresponding mortality was lower (at 30 days, 8 
deaths [0.68%]; at 90 days, 26 deaths [2.2%]; at 1 year, 92 deaths [7.8%]; at 5 years, 400 
deaths [33.8%]; and at 10 years, 759 deaths [64.2%]).
Based on all patients hospitalized with pneumonia, 206 participants (34.85%) had CVD 
events over 10 years after pneumonia hospitalization. Of these, 104 cases (50.5%) were 
myocardial infarction, 35 cases (17.0%) were stroke, and 67 (32.5%) were fatal coronary 
heart disease events. The cumulative number of pneumonia cases that experienced CVD 
events by 30 days after pneumonia were 68 (11.5%); at 90 days, 79 (13.4%); at 1 year, 106 
(17.9%); and at 5 years, 177 (30.0%).
Compared with controls, the 10-year risk of CVD was higher among participants with 
pneumonia (P < .001) (Figure 2). The risk was highest during the first year. During this 
period, CVD occurred in 54 cases (10.6%) and 6 controls (0.5%) in the first 30 days (HR, 
4.07 [95% CI, 2.86-5.27]); 11 cases (2.9%) and 9 controls (0.8%) between 31 and 90 days 
(HR, 2.94 [95% CI, 2.18-3.70]); and 22 cases (6.4%) and 55 controls (5.2%) between 91 
days and 1 year (HR, 2.10 [95% CI, 1.59-2.60]). After the first year, the risk of CVD was 
highest in the second year, when 28 cases (10.3%) and 53 controls (5.4%) developed CVD 
(HR, 1.89 [95% CI, 1.46-2.33]); and lowest in the seventh year, when 4 cases (4.4%) and 27 
controls (4.6%) developed CVD (HR, 1.63 [95% CI, 1.15-2.11]). For reference, the adjusted 
HRs for CVD over 10 years associated with smoking were 1.18; with hypertension, 1.84; 
and with diabetes, 1.19.
The association between pneumonia and increased long-term risk of CVD was observed for 
both severe and nonsevere pneumonia cases (Figure 2). In general, the adjusted HRs for 
severe pneumonia were higher and remained above 1 for longer duration compared with the 
cases of nonsevere pneumonia, but the 95% CIs of these estimates overlapped between the 2 
groups.
Figure 3 shows that the increased hazard for CVD following pneumonia was seen across all 
participants. For instance, the 10-year risk of CVD for a woman aged 72 years who had 2 
cardiovascular risk factors, including hypertension and smoking, increased from 31% 
without pneumonia to 90% with pneumonia (panel B), and was approximately 2-fold higher 
compared with a man aged 77 years with several risk factors including hypertension, 
smoking, elevated low-density lipoprotein cholesterol, high BMI, and chronic kidney 
disease (panel C). Thus, pneumonia hospitalization was associated with a large increase in 
the risk of CVD.
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In sensitivity analyses, the HRs for the association between pneumonia and CVD remained 
similar and significant throughout the 10-year follow-up period when controls included only 
participants who required hospitalization for other causes, when analyses were restricted to 
cases in which pneumonia was recorded in the primary discharge diagnosis field, and when 
participants who were diagnosed with pneumonia and heart failure in the same admission 
were excluded (eTable 4, eTable 5, and eTable 6 in the Supplement).
Atherosclerosis Risk in Communities Study
There were 13 810 eligible participants. After matching, the analysis cohort nested within 
ARIC consisted of 2040 participants (680 pneumonia cases and 1360 controls, Figure 1B). 
After their selection as controls, 22 participants (1.6%) subsequently developed pneumonia. 
The average age of participants with pneumonia was 55 years. Similar to CHS, these 
participants had a high burden of cardiovascular risk factors (Table and eTable 3 in the 
Supplement) and high mortality after pneumonia. The cumulative mortality among 
pneumonia cases at 30 days after pneumonia was 80 deaths (11.8%); at 90 days, 107 deaths 
(15.7%); at 1 year, 168 deaths (24.7%); at 5 years, 300 deaths (44.1%); and at 10 years, 518 
deaths (76.2%). Among controls, the corresponding mortality was also lower (at 30 days, 4 
deaths [0.29%]; at 90 days, 7 deaths [0.51%]; at 1 year, 24 deaths [1.8%]; at 5 years, 116 
deaths [8.5%]; and at 10 years, 286 deaths [21.0%]).
Based on all patients hospitalized with pneumonia, 112 cases (16.5%) had CVD over 10 
years after pneumonia hospitalization (33 cases [29.5%] with myocardial infarction, 36 
cases [32.1%] with stroke, and 43 cases [38.4%] with fatal coronary heart disease). The 
cumulative number of pneumonia cases that developed CVD at 30 days after pneumonia 
were 6 (0.9%); at 90 days, 12 (1.8%); at 1 year, 31 (4.6%); and at 5 years, 70 (10.3%).
Similar to CHS, participants hospitalized with pneumonia had a higher risk of CVD after the 
infection compared with controls (P < .001). The risk was highest during the first year and 
persisted through the second year. During these periods, CVD developed in 4 cases (0.9%) 
and 3 controls (0.3%) in the first 30 days (HR, 2.38 [95% CI, 1.12-3.63]); 4 cases (1.1%) 
and 0 controls (0.0%) between 31 and 90 days (HR, 2.40 [95% CI, 1.23-3.47]); 11 cases 
(3.1%) and 8 controls (0.9%) between 91 days and 1 year (HR, 2.19 [95% CI, 1.20-3.19]); 
and 8 cases (2.6%) and 7 controls (0.8%) during the second year (HR, 1.88 [95% CI, 
1.10-2.66]) (Figure 4). After the second year, the HRs remained elevated but the results 
were not statistically significant. Similar to CHS, pneumonia was associated with a large 
increase in the risk of CVD in younger adults across different risk groups (Figure 3).
Discussion
In this study, hospitalization with pneumonia in older adults was associated with subsequent 
increase in the risk of CVD. The risk was highest (4-fold) in the first 30 days after 
pneumonia and although it progressively declined during the first year, it remained 
approximately 1.5-fold higher in subsequent years. This association persisted after adjusting 
for demographics, the burden of cardiovascular risk factors, and crude measures of frailty, 
and it was observed across a range of infection severity, was validated in a cohort of 
younger adults, and it was robust to sensitivity analyses using different control groups and 
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stringent case definitions for pneumonia hospitalization. Moreover, in our analyses, the 
magnitude of risk for CVD associated with pneumonia was similar or higher compared with 
the risk of CVD associated with traditional risk factors, such as smoking, diabetes, and 
hypertension. Thus, our results suggest that pneumonia is an important risk factor for CVD.
The high short-term risk of CVD within 30 days after infections, mainly of the respiratory 
tract, is well established.3 Nonetheless, results of studies addressing more lasting effects of 
infections on CVD risk have been conflicting. Using case-only analyses, Smeeth and 
colleagues7 and Elkind and colleagues8 found that the association between infection and 
CVD was detected only up to 3 months after infection. However, case-only analyses (self-
controlled cases series and case-crossover designs) are not designed to assess long-term 
effects of acute exposures.33,34 In CHS, we9 previously showed that hospitalization for 
pneumonia was associated with a 2-fold increased risk of death from coronary heart disease 
over 5 years after infection, but we did not adjust for potential confounders, particularly 
cardiovascular risk factors and subclinical CVD before pneumonia. Using medical claims 
data, Foley and colleagues10 reported that septicemia is associated with increased rates of 
CVD up to 5 years after infection. However, they analyzed only patients on dialysis, and 
their results cannot be generalized to the broader population. Thus, this study is the first to 
document the temporal variation in the long-term risk of CVD in adults using rigorous 
methods to adjust for many potential confounders.
The mechanisms by which infections might increase CVD risk in the short-term are 
discussed elsewhere.3,4 However, the mechanism by which infections could affect long-term 
risk of CVD are poorly understood. Experimental models of infection in mice prone to 
atherosclerosis and autopsy studies in humans suggest that infections can induce pro-
inflammatory changes in the cellular composition of the atherosclerotic lesions and make 
them more vulnerable to cause coronary and cerebrovascular events.35,36 Persistent systemic 
inflammatory activity is a known risk factor for CVD.37 Although more than 80% of 
patients hospitalized for pneumonia recover by 1 week, half of these patients continue 
exhibiting high circulating inflammatory markers.38,39 Furthermore, higher interleukin-6 
levels at hospital discharge are associated with increased cardiovascular mortality at 1 year 
after pneumonia.5 Thus, persistent inflammation after pneumonia can contribute to 
subsequent progression to CVD. Similarly, survivors of pneumonia hospitalization may also 
have a persistent procoagulant state, and higher levels of coagulation markers at hospital 
discharge have been associated with increased risk of cardiovascular deaths.6 Finally, organ 
dysfunction during acute infection may persist after recovery and increase risk of CVD. For 
example, acute kidney injury is common during pneumonia and its progression to chronic 
kidney disease could increase cardiovascular risk.40
Our study has several implications. First, because we included only participants without 
CVD prior to pneumonia, our findings suggest that hospitalization for pneumonia should be 
considered an independent cardiovascular risk factor in future strategies for screening and 
primary prevention of CVD. This is particularly important in the elderly because their risk of 
pneumonia and subsequent CVD was high. Second, because previous studies demonstrate 
that patients hospitalized with pneumonia have increased long-term mortality that is not 
explained by their high burden of comorbidities before the infection,11,12 and that CVD is a 
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leading cause of death in these cases,5 our findings should prompt clinical trials to test 
targeted strategies in this population. However, because mortality differences between 
participants with and without pneumonia were attenuated in CHS at 10 years after the 
occurrence of pneumonia in our study, such strategies may not be beneficial in very old 
individuals. Finally, the association of pneumonia with CVD risk should also be considered 
when estimating the cost and benefit of interventions to prevent pneumonia.
Strengths of our study are inclusion of representative community samples of middle-aged 
and elderly adults, large sample size, a validated approach to identify pneumonia events, 
rigorous methodology to adjudicate cardiovascular events, replication of results in another 
cohort, and adjustment for a large number of potential confounders.
Our study also has limitations. First, although we included fatal and nonfatal cardiovascular 
events, we did not account for competing risk of death due to noncardiovascular reasons. 
However, this limitation would bias our estimates toward the null. Second, we did not 
include patients with pneumonia that did not require hospitalization, and thus our results 
cannot be generalized to that population. Third, we ascertained only first hospitalizations for 
pneumonia and thus, our analyses did not account for the potential effect of recurrent 
pneumonia episodes. Fourth, we adjusted for a large number of confounders but could not 
assess the role of pneumococcal vaccination. However, pneumococcal vaccine use is likely 
to be low in ARIC and the magnitude of the association beyond 90 days was similar in both 
cohorts. Thus, pneumococcal vaccination is unlikely to confound this association. Fifth, we 
did not adjust for interventions that could affect the course of pneumonia, such as type of 
antibiotic therapy. This is important because the long-term risk of CVD may be due to a 
combination of the disease itself and accompanying therapies. Finally, because of our 
reliance on administrative data for identification of pneumonia, we cannot rule out 
misclassification bias. Nevertheless, our risk estimates did not meaningfully change when 
we restricted our analyses to cases in which pneumonia was recorded in the primary 
discharge diagnosis field and excluded cases where both pneumonia and heart failure were 
recorded.
Conclusions
Hospitalization for pneumonia is associated with increased short-term and long-term risk of 
CVD, suggesting that pneumonia may be an important risk factor for CVD.
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Figure 1. Selection of the Nested Analysis Cohorts From the Cardiovascular Health Study and 
the Atherosclerosis Risk in Communities Study
ARIC indicates Atherosclerosis Risk in Communities study; CHS, Cardiovascular Health 
Study; CVD, cardiovascular disease. We used an incidence density approach to match 
pneumonia cases to controls. Controls were not hospitalized with pneumonia when matched 
or prior to matching but could develop pneumonia at a later time during follow-up; thus, 54 
controls in CHS and 22 controls in ARIC developed pneumonia after matching.
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Figure 2. Risk of Cardiovascular Disease Events After Hospitalization for Pneumonia in the 
Cardiovascular Health Study
CVD indicates cardiovascular disease. The analysis included 1773 participants (591 
pneumonia cases and 1182 controls). Stratified analyses by severity of pneumonia included 
633 participants (211 pneumonia cases and 422 controls) for pneumonia with organ 
dysfunction and 1140 participants (380 pneumonia cases and 422 controls) for pneumonia 
without organ dysfunction. The number of participants at risk and those who developed an 
event over each time interval were estimated using a complete case approach and 
participants with missing data for covariates were excluded. The estimates were adjusted for 
age, sex, race, hypertension, diabetes mellitus, serum total, high-density lipoprotein and low-
density lipoprotein cholesterol, smoking, alcohol abuse,26 atrial fibrillation, chronic kidney 
disease,27 serum C-reactive protein,28 presence of subclinical cardiovascular disease,29 
percentage of predicted forced expiratory volume in first second of expiration (FEV1) 
measured by spirometry, trajectories of activities of daily living and independent activities 
of daily living over time,30 and trajectories of modified mini-mental status examination 
scores over time.30 Adjusted hazard ratios were calculated using the most recently available 
measurements before inclusion in the nested analysis cohort.
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Figure 3. Adjusted Failure Plots to Show the Magnitude of Risk Increase for Cardiovascular 
Disease That Was Associated With Hospitalization for Pneumonia in CHS and ARIC
ARIC indicates Atherosclerosis Risk in Communities study; BMI, body mass index 
(calculated as weight in kilograms divided by height in meters squared); CHS, 
Cardiovascular Health Study; CVD, cardiovascular disease; LDL, low-density lipoprotein. 
The failure plots are adjusted for demographics and cardiovascular risk factors (see Methods 
for additional details). The plots in brown represent participants with pneumonia and the 
plots in blue represent controls with a covariate pattern in the 25th, 50th, and 75th 
percentiles in CHS and ARIC. The shaded areas around each curve represent 95% CIs.
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Figure 4. Risk of Cardiovascular Disease (CVD) Events After Hospitalization for All Pneumonia 
in the Atherosclerosis Risk in Communities Study
The analysis included 2040 participants (680 pneumonia cases and 1360 controls). The 
number of participants at risk and those who developed an event over each time interval 
were estimated using a complete case approach and participants with missing data for 
covariates were excluded. The estimates were adjusted for age, sex, race, hypertension, 
diabetes mellitus, plasma total, high-density lipoprotein and low-density lipoprotein 
cholesterol, smoking, alcohol abuse,26 atrial fibrillation, chronic kidney disease,27 presence 
of diagnostic Q waves in electrocardiogram, peripheral arterial disease (defined by ankle 
brachial index <0.9), carotid artery wall thickness, presence of carotid atherosclerotic plaque 
by ultrasound, and percentage of predicted forced expiratory volume in first second of 
expiration (FEV1) measured by spirometry. Adjusted hazard ratios were calculated using 
baseline (at study entry) covariates measurements.
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Table
Characteristics of the Nested Analysis Cohorts in the Cardiovascular Health Study and the Atherosclerosis 





Characteristics at Enrollment Pneumonia Cases(n = 591)
Controls




(n = 1360) P Value
Age, mean (SD), y 73.9 (5.8) 72.6 (5.6) <.001 55.8 (5.8) 55.4 (5.9) .12
Women 342 (57.8) 778 (65.8) .001 366 (53.8) 773 (56.8) .20
African Americans 85 (14.4) 157 (13.3) .22 215 (31.7) 333 (24.5) <.001
Atrial fibrillation 38 (6.4) 68 (5.8) .57 0 (0.0) 2 (0.15) c
Diabetes 109 (18.7) 160 (13.6) <.005 106 (15.8) 133 (9.9) <.01
Hypertension 423 (71.6) 911 (77.1) .011 256 (37.8) 430 (31.8) <.001
Chronic kidney diseased 175 (29.9) 319 (27.0) .21 158 (23.7) 293 (21.8) .35
BMI, mean (SD) 26.2 (4.9) 26.9 (5.0) <.002 27.6 (6.2) 27.3 (5.3) .29
Ever smokers 381 (64.5) 664 (56.2) <.001 492 (72.4) 750 (55.2) <.001
 Pack-years, median (IQR) 6.5 (0.0-9.0) 0.0 (0.0-22.0) <.001 20.1 (0.0-40.0) 1.95 (0.0-24.2) <.001
Alcohol abuse 33 (5.6) 56 (4.7) .44 79 (11.8) 136 (10.1) .24
LDL, mg/dL
 <100 158 (27.3) 235 (20.0)
<.001
125 (19.2) 224 (17.0)
.47 100-129 196 (33.9) 390 (33.2) 176 (27.1) 366 (27.7)
 ≥130 224 (38.8) 549 (46.8) 349 (53.7) 730 (55.3)
HDL, mg/dL
 <35 30 (5.1) 43 (3.7)
.32
108 (16.2) 153 (11.4)
.008 35-59 365 (60.9) 738 (62.6) 388 (58.4) 803 (60.1)
 ≥60 199 (34.0) 398 (33.8) 169 (24.4) 381 (28.5)
Total cholesterol, mg/dL
 <200 289 (49.3) 540 (45.8)
.32
258 (38.8) 503 (37.6)
.86 200-239 201 (34.3) 431 (35.7) 248 (37.3) 503 (37.6)
 ≥240 96 (16.4) 219 (18.6) 159 (23.9) 331 (24.8)
Serum CRP, median (IQR), mg/L 2.67 (1.29-4.98) 2.27 (1.19-4.07) .002


















Characteristics at Enrollment Pneumonia Cases(n = 591)
Controls




(n = 1360) P Value
Percentage of predicted FEV1, mean 
(SD)
84.7 (23.9) 94.7 (20.4) <.001 81.9 (22.9) 95.3 (16.3) <.001
Subclinical CVDe 408 (69.0) 719 (60.8) <.001
Diagnostic Q waves on 
electrocardiogram 3 (0.4) 2 (0.2) .33
Ankle brachial index <0.9 47 (6.9) 38 (2.8) <.001
Carotid artery wall thickness, mm 0.77 (0.21) 0.72 (0.18) <.001
Carotid atherosclerotic plaque on 
ultrasound 283 (41.6) 711 (52.3) <.001
Longitudinal Trajectories
Activities of daily livingf
 No decline 430 (72.8) 893 (75.6)
.001 Minimal decline 115 (19.5) 242 (20.5)
 Rapid decline 46 (7.8) 47 (4.0)
Independent activities of daily livingf
 No decline 404 (68.4) 900 (76.1)
<.001
 Rapid decline 187 (31.6) 282 (23.9)
Cognition based on mini-mental state scoref
 No decline 420 (71.1) 949 (80.3)
<.001 Minimal decline 129 (21.8) 190 (16.1)
 Rapid decline 42 (7.1) 43 (3.6)
Abbreviations: ARIC, Atherosclerosis Risk in Communities; BMI, body mass index (calculated as weight in kilograms divided by height in meters 
squared); CHS, Cardiovascular Health Study; CRP, C-reactive protein; CVD, cardiovascular disease; FEV1, forced expiratory volume in first 
second; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein.
SI conversion factors: To convert HDL, LDL, and total cholesterol to mmol/L, multiply by 0.0259.
a
Values represent the most recent available measurement before inclusion into the analysis cohort.
b
Values represent measurements at enrollment in ARIC.
c
Estimation of a P value is not valid due to the low number of events.
d
Defined as glomerular filtration rate <60 mL/min/1.73 m2 estimated by the Modification of Diet in Renal Disease study equation.27
e
Subclinical disease was defined as having any 1 of the following: (1) major electrocardiogram abnormalities based on the Minnesota Code, (2) 
ankle-brachial index of ≤0.9, (3) increased carotid or internal carotid artery wall thickness (>80th percentile of the CHS distribution) or stenosis of 
>25% (based on ultrasonographic findings), (4) echocardiogram wall motion abnormality or low ejection fraction, or (5) positive responses to the 
Rose Questionnaire for angina or intermittent claudication (without clinical history of these diagnoses).29
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f
Participants on trajectories of no and minimal decline had either normal or borderline scores (score <79 suggests dementia) throughout the study. 
Participants on trajectories of no and minimal decline for activities of daily living (ADL) and independent ADL (IADL) required assistance for ≤1 
ADLs or IADLs. Additional information on the calculation of these trajectories is provided in eMethods 2 of the Supplement.30
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